SCHEMBL4475659

SCHEMBL4475659

CC(C)(C)OC(=O)Nc1csnc1C1CCCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.48
JAK1 P23458 3/20 0.48
TYK2 P29597 2/20 0.48
JAK3 P52333 2/20 0.48
PARP1 P09874 1/20 0.43
BCL9 O00512 6/20 0.43
CTNNB1 P35222 6/20 0.43
USP30 Q70CQ3 2/20 0.42
PDE4B Q07343 1/20 0.42
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
HTT P42858 1/20 0.40
PRMT5 O14744 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4607070 0.84 JAK2 (0.38) JAK2JAK1USP30
SCHEMBL4475037 0.82 BCL9 (0.47) JAK2JAK1TYK2JAK3PARP1
SCHEMBL4469972 0.80 JAK2 (0.53) JAK2JAK1TYK2JAK3BCL9
SCHEMBL4477032 0.80 JAK2 (0.53) JAK2JAK1TYK2JAK3BCL9
SCHEMBL8427795 0.79 JAK2 (0.47) JAK2JAK1TYK2JAK3PARP1
SCHEMBL4478755 0.78 JAK2 (0.49) JAK2JAK1TYK2JAK3BCL9
SCHEMBL15669949 0.77 USP30 (0.53) JAK2JAK1TYK2JAK3PARP1
SCHEMBL2063483 0.77 USP30 (0.58) USP30PDE4BITGB3ITGA2BHTT
SCHEMBL2063481 0.77 USP30 (0.58) USP30PDE4BITGB3ITGA2BHTT
SCHEMBL6128873 0.77 USP30 (0.58) USP30PDE4BITGB3ITGA2BHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576085-B2 Imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION (US) 2009-08-18 US disclosed
CN-101370811-A Imidazopyrazine compounds as protein kinase inhibitors SCHERING CORP (US) 2009-02-18 CN disclosed
EP-1945216-A1 METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION (US) 2008-07-23 EP disclosed
EP-1945644-A2 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2008-07-23 EP disclosed
WO-2007058942-A2 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2007-05-24 WO disclosed
US-20070117804-A1 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION 2007-05-24 US disclosed
WO-2007056468-A1 METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION (US) 2007-05-18 WO disclosed
US-20070105864-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-05-10 US disclosed
US-20060106023-A1 Novel imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106023-A1 Novel imidazopyrazines as cyclin dependent kinase inhibitors CDK2, CDKN1A, CDK1 JAK2 143/4885JAK1 110/4885TYK2 357/4885
US-20070117804-A1 Imidazopyrazines as protein kinase inhibitors CHEK1, CHEK2, CDKN1A JAK2 71/4885JAK1 62/4885TYK2 120/4885
US-20070105864-A1 Methods for inhibiting protein kinases PIM1, PIM2, PIM3 JAK2 170/4885JAK1 86/4885TYK2 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.